Intervention

Anti-PD-1 monoclonal antibody

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting2

Common conditions9

Lead sponsors shown5

Clinical trials

5 shown

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPCNCT07090148 · 2026-03-03

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsNCT05941507 · 2023-10-05

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung CancerNCT05987345 · 2023-07-06

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILsNCT05556200 · 2022-12-01

Precise Therapy for Refractory HER2 Positive Advanced Breast CancerNCT05429684 · 2021-01-01

Common conditions

Advanced Solid Tumors1 Breast Cancer1 HER2+ Breast Cancer1 Non-castrate Prostate Cancer1 NSCLC1 Oligometastatic Prostate Cancer (OMPC)1 Prostate Cancer Patients1 Recurrent Prostate Cancer1 Triple-Negative Breast Cancer1

Leading sponsors

Energenx Medical LTD.1 First Affiliated Hospital Xi'an Jiaotong University1 LigaChem Biosciences, Inc.1 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1 University of Wisconsin, Madison1

Trial status mix

UNKNOWN3

RECRUITING2

Phase mix

PHASE12

PHASE22

NA1

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.